HemaSphere Journal

This paper shows that Tet2 is essential for controlling how IgG1⁺ germinal center B cells mature. The authors reveal that Tet2 loss disrupts the balance between proliferation and differentiation, offering insight into mechanisms that may drive DLBCL transformation 👉https://bit.ly/4pI3Psx

The authors report that IMWG‑FI–defined frail patients form a diverse group, with ultra‑frail patients facing very limited survival. Their findings stress the value of including frailty categories in future research and clinical planning.

Read more here 👉https://bit.ly/4pw4iim

Real-world cases illustrate how luspatercept use in transfusion-dependent β-thalassemia hinges on genotype-informed selection, patient engagement, and nuanced monitoring of efficacy and safety, offering practical insights beyond clinical
trial data.

Read the details here👉https://bit.ly/46KtU3u

This issue highlights research on clonal hematopoiesis in #CLL/Richter transformation, TKI response patterns in #CML, venetoclax‑based therapy outcomes in #AML, challenges in #AL amyloidosis trial eligibility & advances in #MRD & flow‑cytometry–based prognostics. 👉https://bit.ly/4qFeK6Q

Venetoclax-sensitizing genomics drive markedly better outcomes in therapy-related AML, where venetoclax-based regimens boost responses and enable more patients to reach transplant, while TP53 and RAS mutations continue to limit survival.

https://bit.ly/4rJdb8M

This paper shows that memantine was safe and well tolerated in patients with sickle cell disease #SCD. Authors report reduced red blood cell K⁺ loss and improved hemoglobin at low doses, suggesting a promising supportive therapy. 

Delve deeper 📰 https://bit.ly/3YAax8P

This paper shows that IGHV gene usage and a 97% IGHV identity cutoff offer meaningful prognostic insight in #mantlecell lymphoma. The authors provide evidence that immunoglobulin repertoire patterns may help refine risk assessment. Explore the full analysis 👉 https://bit.ly/4qD0SLi

Authors explore how to distinguish defective vs. ineffective erythropoiesis, offering insights into mechanisms underlying anemia & hematologic disorders. https://bit.ly/4jTjsfl

@ElHoss_Sara

This paper shows that adult #LBCL with IRF4 rearrangement is biologically diverse. The authors highlight how age, tumor site, and molecular features together can refine diagnosis and support more precise risk assessment and management.

Go in depth here 👉https://bit.ly/49KYlqU

Fabulous! Congratulations and well done.

This paper demonstrates how authors applied machine‑learning methods to reclassify patients with persistent cytopenias. Their model consistently identified individuals likely to have telomere biology disorders, supporting more precise diagnostic evaluation.

👉https://bit.ly/4qsrgqM

Blinatumomab in De Novo AYA ALL - Dr Matthew Greenwood Quickly and easily listen to HemaSphere Podcast for free!

🔥 New Episode Alert!

New episode! Dr Charley de Bock talks with Dr Matthew Greenwood about replacing consolidation chemo with blina in AYA B‑ALL—plus MRD‑guided care, menin inhibitors & more. Big shifts ahead in ALL. 🎧

This paper reveals how dual inheritance of SEC23B and PIEZO1 pathogenic variants amplifies erythropoietic stress and ferritin accumulation. The authors provide evidence that multi‑locus genetics can significantly alter disease outcomes.

Go in depth 👉https://bit.ly/3NOkP2Y

LBCL Guidelines Webinar Series - The European Hematology Association (EHA)

EHA is hosting a 4‑part webinar series (12 Mar–early Apr 2026) to help hematologists apply the EHA Clinical Practice Guidelines for aggressive LBCL in real‑world care.
Expert insights, case discussions & Q&A included.
Register now! 🔗 bit.ly/4rYV92u

🌟 A fantastic Editors meeting in The Hague! 🌟

Great to see our Editors, Wiley & EHA team together in person. The day was filled w/ discussions, forward‑thinking planning & of course plenty of camaraderie. Looking forward to all that we’ll accomplish together ahead!

https://bit.ly/4kFifZH

This paper reports that authors identify molecular patterns linked to primary resistance to VEN–HMA therapy, including a higher BCL‑XL/BCL‑2 ratio and frequent TP53 mutations. These findings point to potential therapeutic strategies worth exploring

Read more in depth 👉https://bit.ly/3Lllpo9

This recently published paper shows that patients with #MPNs experience notable impairments in daily functioning, especially fatigue. The authors highlight that clinicians often underestimate symptom burden, reinforcing the need for routine patient‑reported outcomes 👉https://bit.ly/4q2Zwcb

The authors report that non‑TCR TLX1‑positive #T‑ALL arises mainly from chromosomal changes that reposition ANKRD1 and PCGF5 enhancers near TLX1. This paper links this mechanism to distinct disease features and reduced survival.

Dig deeper👉https://bit.ly/4sqiyLh

This paper shows that venetoclax‑rituximab retreatment can achieve renewed clinical responses in patients with relapsed CLL/SLL who previously stopped therapy after a deep response. Authors highlight its potential to extend long‑term disease control.

In depth 👉 https://bit.ly/44Sa9Gu

In this paper, authors report that elevated baseline sVCAM‑1 and sIL‑2R identify patients at higher risk for prolonged neutropenia, severe infections, and inferior survival after CAR‑T therapy. Authors suggest these markers can support more individualized management.👉https://bit.ly/3Kzsv88

According to authors,  long‑term benefit from anti‑BCMA CAR‑T in RRMM is driven more by a patient’s immune profile and tumor burden than by CAR‑T‑cell features. The authors propose a risk score to help identify patients most likely to achieve durable responses 👉https://bit.ly/499jE6I

In this Review authors discuss that atypical #CML has sig. dx challenges, diverse mutations & no standard of care, stressing need for better prognostic tools & confirm that allogeneic transplant remains the sole curative therapy, w/ targeted agents under investigation👉https://bit.ly/3XL9xOM

Daratumumab‑based treatment leads to rapid, deep responses in #AL amyloidosis. The authors highlight that achieving a very good partial response within one month strongly predicts longer EFS and OS.

Read more about the process https://bit.ly/4qCIL7t

This Editorial stresses the need for harmonized research, consistent clinical standards, better training, and stronger global coordination in #hemoglobinopathies. The authors propose practical steps to address these long‑standing challenges.

Read how 👉 https://bit.ly/4pPzqZK

This paper indicates that #PMBL relapse after #CAR‑T requires quick, individualized decisions. The authors highlight checkpoint inhibitor–based regimens as a preferred option and call for coordinated input from multiple specialists.

Read more about the findings here https://bit.ly/48FqYVZ

Authors demonstrate that impaired CAR T cell function in #CLL may stem from greater exhaustion and microenvironmental suppression, highlighting that IL 10 or CXCR4 inhibition can significantly improve cytotoxicity in a 3D co culture model.

Read more about this here https://bit.ly/48FY0Fn

Findings in this paper report that the 𝘝𝘏𝘓ᴿ²⁰⁰ᵂ mutation increases erythropoietin and transferrin, both tied to suppressed hepcidin. This suggest a model where iron balance and HIF‑driven erythropoiesis act together to regulate hepcidin.

Read more in depth 👉 https://bit.ly/48ASZxW

🚨In this extended episode host Sci Ed Charles de Bock discusses #SCD w/ co-authors, covering both expert & lived-patient perspectives

This episode is on our website & all major podcast platforms. Listen & enjoy casual, insightful discussions about #hematology research https://bit.ly/4nIhH68

This recent HemaTopics from Scientific Editor S Hibbs underlines that discussions of “cure” in #SCD must consider medical, emotional, and social dimensions. Authors encourage clinicians to communicate with nuance, clarity, and awareness of individual experience. 👉 https://f.mtr.cool/spprnmlkcs

Authors in this recently published paper show that MMS22L plays a critical role in red cell formation. Its reduced function, together with CDAN1 defects, impairs erythroid development and offers fresh insight into congenital dyserythropoietic anemia.

📰https://bit.ly/3YthgS9